Biotech group Proteome Sciences has agreed to work with CHDI Foundation Inc on a systems biology project regarding Huntington's disease.
Initially, Proteome will provide its PS Biomarker Services protein profiling to CHDI's research programmes. The analyses will be performed at Proteome's facility in Frankfurt, Germany.
"We are delighted that CHDI has selected PS Biomarker Services to deliver potential proteomic markers that could help elucidate mechanisms of Huntington's disease pathology," said Proteome' Chief Operating Officer Ian Pike.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
"The link between the Huntington's disease genotype and disease phenotype remains poorly understood and we will apply our Tandem Mass Tag workflows to provide high density protein expression maps in cell lines carrying different CAG-repeat lengths," he said.
-
Cash in on the growth prospects of Europe's companiesOpinion Marcel Stötzel, co-portfolio manager of the Fidelity European Trust, selects three stocks
-
Is the AI boom another dotcom bubble?25 years on from the dotcom bubble bursting, is it time for investors to consider the sustainability of the AI boom in the stock market?
